• Respiri (RSH) has secured its first primary care specialty practice in Georgia, US
• As such, the company has welcomed its first patients with respiratory disorders to begin the ‘wheezo’ remote patient monitoring program
• Through the program, Respiri’s remote patient monitoring (RPM) partner, Access Telehealth, will offer a full solution that includes the Remotli platform, patient engagement, and remote monitoring for patients suffering from asthma
• Respiri says it will generate revenues from device sales — up to US$60 per wheezo device (just under A$90) — plus a monthly fee per patient per month of up to US$20
• Respiri is up 11.11 per cent and trading at 4 cents at 11:00 am AEDT

Respiri (RSH) has secured its first primary care specialty practice in Georgia, US.

As such, the company has welcomed its first patients with respiratory disorders to begin the ‘wheezo’ remote patient monitoring program.  

Through the program, Respiri’s remote patient monitoring (RPM) partner, Access Telehealth, will offer a full solution that includes the Remotli platform, patient engagement, and remote monitoring for patients suffering from asthma.

Reimbursement codes from this program will then be processed through Medicaid Services and private insurers.

Respiri said it would generate revenues from device sales — roughly US$60 per device (just under A$90) — plus a monthly fee per patient per month of up to US$20.

Respiri has now secured customers located in five different states across the US that treat and manage paediatric patients with asthma, elderly patients with chronic obstructive pulmonary disease (COPD), and respiratory complications.“Although respiratory specialists remain our key targets for wheezo RPM, the fact remains that family medical practitioners are heavily involved in the management of patients with asthma and COPD,” CEO Marjan Mikel said.

“Having wheezo RPM prescribed by this group for the management of respiratory disorders should help improve patient well-being and reduce disease complications and further broaden our program patient reach.

“I was also present as three patients commenced on wheezo and the relief they expressed knowing that they now have an ‘early warning system’ connected to their physician presented the first-hand experience of why our business is so important.”

Respiri and its RPM partners said they would continue discussions with other potential wheezo RPM healthcare organisations.

Respiri was up 11.11 per cent and trading at 4 cents at 11:00 am AEDT.